Skip to main content

High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial.

Virchows Archiv : an international journal of pathology

Authors: Oliver Hommerding, Marit Bernhardt, Tobias Kreft, Anna Scherping, Mahmoud Abbas, Gustavo Baretton, Jan Hinrich Bräsen, Johannes Breyer, Christopher Darr, Franz Friedrich Dressler, Jörg Ellinger, Ramona Erber, Irene Esposito, Arndt Hartmann, Wolfgang Hartmann, Barbara Heitplatz, Hans Kreipe, Marcel Lafos, Johannes Linxweiler, Cristina Lopez-Cotarelo, Verena Sailer, Henning Reis, Matthias Saar, Hans-Ulrich Schildhaus, Katrin Schlack, Matthias Schmid, Maximilian Seidl, Axel Semjonow, Ulrich Sommer, Phillip Rolf Stahl, Verena Tischler, Florian Weber, Anna-Lena Wulf, Bernd Wullich, Glen Kristiansen

The prognostication of individual disease trajectory and selection of optimal therapy in patients with localized, low-grade prostate cancer often presents significant difficulty. The phosphatase and tensin homolog on chromosome 10 (PTEN) has emerged as a potential novel biomarker in this clinical context, based on its demonstrated prognostic significance in multiple retrospective studies. Incorporation into standard clinical practice necessitates exceptional diagnostic accuracy, and PTEN's binary readout-retention or loss-suggests its suitability as a biomarker. This multi-institutional ring trial aimed to validate the diagnostic precision of PTEN immunohistochemistry in localized, low- to intermediate-risk prostate cancer, across ten university pathology institutes in Germany. The trial incorporated 90 cases of patients diagnosed with acinar adenocarcinoma of the prostate of grade groups 1 (n = 8, 8.9%) and 2 (n = 82, 91.1%) post-radical prostatectomy. Remarkably, the interpretation of PTEN immunohistochemistry displayed substantial variation (12.5-51.2% PTEN loss rates) within an identical cohort of prostate cancer. Fluorescence in situ hybridization analysis demonstrated PTEN hemizygous deletions in 5.5% (5/90) of cases. All cases with hemizygous deletions presented a distinct loss of PTEN expression by immunohistochemistry and were unanimously identified as PTEN loss by all participants (sensitivity 100%). However, negative (loss) immunohistochemistry was relatively non-specific for an underlying genomic deletion. Improved inter-observer agreement was observed in a subsequent ring trial. Finally, we identify S473-pAKT immunohistochemistry as a useful marker in equivocal cases. In summary, this multi-institutional ring trial illustrates surprisingly heterogeneous outcomes in defining PTEN status by immunohistochemistry.

© 2024. The Author(s).

PMID: 39653828

Participating cluster members